TrialThe Lancet. Oncology2026

Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.

Andrea Necchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.